RESPONSIVENESS OF PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS®) COMPUTERIZED ADAPTIVE TESTS (CATS) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

S. Kasturi, J. Szymonik, J. Bernard, K. Kirou, A. Levine, L. Sammaritano, L. A. Mandt, M. A. Padula, I. Rheumatology, Tufts Medical Center, Boston, M. A. Padula, Immunopathology Laboratory, San Carlo Hospital, Potenza, Italy

Background: The accurate measurement of patient-reported outcomes is a priority for patient-centered care in SLE, a chronic systemic disease with significant impact on quality of life. PROMIS CATs are precise measures of physical, mental, and social health with construct validity in SLE. The longitudinal responsiveness (sensitivity to change) of PROMIS CATs in SLE patients is unknown.

Objectives: To evaluate the responsiveness of PROMIS CATs in SLE outpatients using patient and physician-derived anchors.

Methods: Adult SLE patients were recruited from an SLE Center of Excellence. Subjects completed 14 selected PROMIS CATs at two visits a minimum of one month apart. SLE disease activity was measured with a patient global assessment of change, a physician global assessment, and the physician-derived SELENA-SLEDAI. Responsiveness of PROMIS scores was evaluated using known-groups validity. Effect sizes were compared across groups of patients who differed in their patient global assessment of change, physician global assessment, and SELENA-SLEDAI using Wilcoxon rank-sum tests.

Results: A diverse cohort of 228 SLE patients, including 45 (19.8%) patients flaring by SELENA-SLEDAI, completed baseline surveys. Follow up surveys were completed by 190 (83%). There was poor agreement between patient and physician global assessments of change, a physician global assessment, and the physician-derived SELENA-SLEDAI. Responsiveness of PROMIS scores was evaluated using known-groups validity. Effect sizes were compared across groups of patients who differed in their patient global assessment of change, physician global assessment, and SELENA-SLEDAI using Wilcoxon rank-sum tests.

Conclusions: PROMIS CATs showed modest responsiveness to patient-reported changes in lupus health status in domains of anger, pain interference, and physical function. These data suggest that certain PROMIS CATs are precise and sensitive tools which may be used to measure and monitor important aspects of the patient experience of lupus not captured by physician-derived metrics. Further studies are needed to evaluate the responsiveness of PROMIS CATs in populations with greater SLE disease activity and more regular follow-up.

Acknowledgements: Funding was provided by the Rheumatology Research Foundation Scientist Development Award.

Disclosure of Interest: None declared


VALIDITY OF THREE 0–10 VISUAL ANALOG SCALES (VAS) FOR QUANTITATIVE PHYSICIAN ASSESSMENT OF INFLAMMATION, DAMAGE, AND DISTRESS TO SUPPLEMENT A PHYSICIAN GLOBAL ASSESSMENT 0–10 VAS

T. Pinus, L. Castrejon, J. A. Block, R. Rheumatology, Rush University Medical Center, Chicago, United States

Background: Rheumatologists generally view their primary goal as control of inflammation in order to prevent long-term damage, and quantitative assessment involves measures of inflammatory activity (lab tests, joint counts, and indices). Although structural damage and patient distress (fibromyalgia, depression, etc.) are widely recognized, these problems generally are described narratively, and not assessed quantitatively. Recent advances in control of inflammation, as well as increased degenerative diseases in an aging population and recognition of a high prevalence of fibromyalgia, may have shifted rheumatologists’ patient mix more prominently toward damage and distress vs. inflammation.

Objectives: To analyze physician global assessment (DOCGL) on a 0–10 visual analog scales (VAS), and 3 additional 0–10 VAS for inflammation, damage, and distress, as well as estimates of the proportion of each to explain DOCGL.

Methods: Rheumatologists at one academic site complete a 0–10 DOCGL VAS, 3 further 0–10 VAS to assess inflammation (reversible disease) (DOCINF), joint and other organ damage (irreversible disease) (DOCDAM), and patient distress (fibromyalgia, depression, etc.) (DOCSTR), in routine care. The proportion of DOCGL attributed to inflammation, damage, and distress (total=100%) also is estimated. Mean values were analyzed in a cross-sectional study of 570 patients, and compared in subgroups with rheumatoid arthritis (RA), osteoarthritis (OA), or fibromyalgia (FM), using tests and analysis of variance (ANOVA).

Results: Mean DOCGL VAS was 4.4±10 in all patients, 4.4 in 131 with OA, 4.6 in 98 with RA, and 5.2 in 89 with FM (table 1). Highest mean scores were seen for DOCINF in RA, DOCDAM in OA, and DOCSTR in FM (p<0.001), indicating face validity. Nonetheless, mean DOCDAM was higher than DOCINF in all groups, including RA, and mean estimates of the proportion of DOCGL attributed to damage was greater than to inflammation in all groups (table 1). Scores for DOCSTR were higher than for DOCINF in all groups other than RA.

Acknowledgements: The authors would like to express their special appreciation and thanks to Prof. Ignazio Olivieri who died on July 28th, 2017. He was an example of strength and tenacity with a contagious enthusiasm for a rigorous scientific research.

Disclosure of Interest: None declared